THE DEAL, AT A GLANCE
1/4 reviewedNanopath
01What it doesNanopath is commercializing molecular diagnostic technology intended to diagnose diseases at the point of care.Source-grounded · automated review · Explore ↗
Checked 2026-11-15 · Review due 2026-11-22
Read supporting source ↗Nanopath is commercializing a first-in-class…
02What happenedNanopath raised $25M Series B, announced 2026-11-10From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersNanopath's $25M Series B places the round at the 54th percentile by size among tracked Unclassified rounds, indicating a round near the middle of the category's…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Nanopath · Financing Record
Explore source-linked visual explanations for Nanopath. Unsupported claims are withheld while source review continues.
Record 15742 · Recorded date: 2026-11-10
What it does
Our vision is to develop novel diagnostic technologies to equitably improve human health.
Source: nanopath.com ↗